Phase II study of vlnorelbine in patients with hormone refractory prostate cancer

Armelle Caty, Dominique Chopin(Hospices Civils de Lyon), Ph. Houyau, E. Favreau, T. Gil, Patricia Tresca(Pierre Fabre (France)), M. Beauduin, Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Ph. Montcuquet, Etienne Suc, J. Breza, Yves Humblet(Deventer Ziekenhuis), F. Rolland(Institut de Cancérologie de l'Ouest), Xizi Sun

European Journal of Cancer

September 1, 1997

10.1016/s0959-8049(97)84523-6

Cited by 6

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|645

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

|Journal of Clinical Oncology|2009|643

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

|Annals of Oncology|2014|603

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

|Nature|2021|603